APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal

Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.

Selected research

Market Outlook & Growth Opportunities

Global Gastrointestinal Market Outlook and Growth Opportunities 2026

23 December 2025194 pages

Choose your research edition.

Industry ResearchGastrointestinal Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.

Global Gastrointestinal key players include AstraZeneca, Sanofi, Bayer, Pfizer, GlaxoSmithKline, etc. Global top five manufacturers hold a share over 25%.

Europe is the largest market, with a share about 45%, followed by Asia, and North America, both have a share over 45 percent.

Read the full market overview

In terms of product, Prescription Gastrointestinal Drug is the largest segment, with a share over 80%. And in terms of application, the largest application is Chronic Gastritis, followed by Peptic Ulcer, etc.

This report provides an overview of the global Gastrointestinal market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastrointestinal and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastrointestinal revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gastrointestinal market.

Gastrointestinal Segment by Company

AstraZenec

Sanofi

Bayer

Pfizer

GlaxoSmithKline

Teva

Zeria（Tillotts）

Perrigo

Boehringer Ingelheim

Purdue Pharma

C.B. Fleet

Abbott

Jiangzhong

Xian-Janssen

Gastrointestinal Segment by Type

Prescription Gastrointestinal Drug

OTC Gastrointestinal Drug

Gastrointestinal Segment by Application

Chronic Gastritis

Functional Dyspepsia

Peptic Ulcer

Acute Gastroenteritis

Others

Gastrointestinal Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gastrointestinal status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gastrointestinal key companies, revenue, market share, and recent developments.

3. To split the Gastrointestinal breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gastrointestinal market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gastrointestinal significant trends, drivers, influence factors in global and regions.

6. To analyze Gastrointestinal competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastrointestinal industry.

Chapter 3: Detailed analysis of Gastrointestinal company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gastrointestinal in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gastrointestinal in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gastrointestinal Industry Trends Table 2. Gastrointestinal Industry Drivers Table 3. Gastrointestinal Industry Opportunities and Challenges Table 4. Gastrointestinal Industry Restraints Table 5. Global Gastrointestinal Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gastrointestinal Revenue Share by Company (2021-2026) Table 7. Global Gastrointestinal Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gastrointestinal Key Company Manufacturing Base & Headquarters Table 9. Global Gastrointestinal Company, Product Type & Application Table 10. Global Gastrointestinal Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gastrointestinal by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Prescription Gastrointestinal Drug Table 15. Significant Companies of OTC Gastrointestinal Drug Table 16. Global Gastrointestinal Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Gastrointestinal Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Gastrointestinal Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Gastrointestinal Sales Value Share by Type (2021-2026) Table 20. Global Gastrointestinal Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Chronic Gastritis Table 22. Significant Companies of Functional Dyspepsia Table 23. Significant Companies of Peptic Ulcer Table 24. Significant Companies of Acute Gastroenteritis Table 25. Significant Companies of Others Table 26. Global Gastrointestinal Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gastrointestinal Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Gastrointestinal Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Gastrointestinal Sales Value Share by Application (2021-2026) Table 30. Global Gastrointestinal Sales Value Share by Application (2027-2032) Table 31. Global Gastrointestinal Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Gastrointestinal Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Gastrointestinal Sales Value Share by Region (2021-2026) Table 34. Global Gastrointestinal Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Gastrointestinal Sales Value Share by Region (2027-2032) Table 36. Global Gastrointestinal Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Gastrointestinal Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Gastrointestinal Sales Value Market Share by Country (2021-2026) Table 39. Global Gastrointestinal Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Gastrointestinal Sales Value Market Share by Country (2027-2032) Table 41. AstraZenec Company Information Table 42. AstraZenec Business Overview Table 43. AstraZenec Gastrointestinal Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. AstraZenec Gastrointestinal Product Portfolio Table 45. AstraZenec Recent Development Table 46. Sanofi Company Information Table 47. Sanofi Business Overview Table 48. Sanofi Gastrointestinal Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Sanofi Gastrointestinal Product Portfolio Table 50. Sanofi Recent Development Table 51. Bayer Company Information Table 52. Bayer Business Overview Table 53. Bayer Gastrointestinal Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Bayer Gastrointestinal Product Portfolio Table 55. Bayer Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Gastrointestinal Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Pfizer Gastrointestinal Product Portfolio Table 60. Pfizer Recent Development Table 61. GlaxoSmithKline Company Information Table 62. GlaxoSmithKline Business Overview Table 63. GlaxoSmithKline Gastrointestinal Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. GlaxoSmithKline Gastrointestinal Product Portfolio Table 65. GlaxoSmithKline Recent Development Table 66. Teva Company Information Table 67. Teva Business Overview Table 68. Teva Gastrointestinal Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Teva Gastrointestinal Product Portfolio Table 70. Teva Recent Development Table 71. Zeria（Tillotts） Company Information Table 72. Zeria（Tillotts） Business Overview Table 73. Zeria（Tillotts） Gastrointestinal Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Zeria（Tillotts） Gastrointestinal Product Portfolio Table 75. Zeria（Tillotts） Recent Development Table 76. Perrigo Company Information Table 77. Perrigo Business Overview Table 78. Perrigo Gastrointestinal Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Perrigo Gastrointestinal Product Portfolio Table 80. Perrigo Recent Development Table 81. Boehringer Ingelheim Company Information Table 82. Boehringer Ingelheim Business Overview Table 83. Boehringer Ingelheim Gastrointestinal Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Boehringer Ingelheim Gastrointestinal Product Portfolio Table 85. Boehringer Ingelheim Recent Development Table 86. Purdue Pharma Company Information Table 87. Purdue Pharma Business Overview Table 88. Purdue Pharma Gastrointestinal Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Purdue Pharma Gastrointestinal Product Portfolio Table 90. Purdue Pharma Recent Development Table 91. C.B. Fleet Company Information Table 92. C.B. Fleet Business Overview Table 93. C.B. Fleet Gastrointestinal Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. C.B. Fleet Gastrointestinal Product Portfolio Table 95. C.B. Fleet Recent Development Table 96. Abbott Company Information Table 97. Abbott Business Overview Table 98. Abbott Gastrointestinal Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Abbott Gastrointestinal Product Portfolio Table 100. Abbott Recent Development Table 101. Jiangzhong Company Information Table 102. Jiangzhong Business Overview Table 103. Jiangzhong Gastrointestinal Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. Jiangzhong Gastrointestinal Product Portfolio Table 105. Jiangzhong Recent Development Table 106. Xian-Janssen Company Information Table 107. Xian-Janssen Business Overview Table 108. Xian-Janssen Gastrointestinal Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. Xian-Janssen Gastrointestinal Product Portfolio Table 110. Xian-Janssen Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Gastrointestinal Product Image Figure 2. Global Gastrointestinal Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastrointestinal Market Size (2021-2032) & (US$ Million) Figure 4. Global Gastrointestinal Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Prescription Gastrointestinal Drug Image Figure 8. OTC Gastrointestinal Drug Image Figure 9. Global Gastrointestinal Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Gastrointestinal Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Gastrointestinal Sales Value Share by Type (2021-2032) Figure 12. Chronic Gastritis Image Figure 13. Functional Dyspepsia Image Figure 14. Peptic Ulcer Image Figure 15. Acute Gastroenteritis Image Figure 16. Others Image Figure 17. Global Gastrointestinal Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gastrointestinal Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Gastrointestinal Sales Value Share by Application (2021-2032) Figure 20. Global Gastrointestinal Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Gastrointestinal Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Gastrointestinal Sales Value (2021-2032) & (US$ Million) Figure 23. North America Gastrointestinal Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Gastrointestinal Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Gastrointestinal Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Gastrointestinal Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Gastrointestinal Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Gastrointestinal Sales Value (2021-2032) & (US$ Million) Figure 29. South America Gastrointestinal Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Gastrointestinal Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Gastrointestinal Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Gastrointestinal Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Gastrointestinal Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Gastrointestinal Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Gastrointestinal Drug
  • OTC Gastrointestinal Drug
Applications
  • Chronic Gastritis
  • Functional Dyspepsia
  • Peptic Ulcer
  • Acute Gastroenteritis
  • Others
Companies covered
  • AstraZenec
  • Sanofi
  • Bayer
  • Pfizer
  • GlaxoSmithKline
  • Teva
  • Zeria（Tillotts）
  • Perrigo
  • Boehringer Ingelheim
  • Purdue Pharma
  • C.B. Fleet
  • Abbott
  • Jiangzhong
  • Xian-Janssen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gastrointestinal Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gastrointestinal Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gastrointestinal Market Dynamics
  1. 2.1 Gastrointestinal Industry Trends
  2. 2.2 Gastrointestinal Industry Drivers
  3. 2.3 Gastrointestinal Industry Opportunities and Challenges
  4. 2.4 Gastrointestinal Industry Restraints
3 Gastrointestinal Market by Company
  1. 3.1 Global Gastrointestinal Company Revenue Ranking in 2025
  2. 3.2 Global Gastrointestinal Revenue by Company (2021-2026)
  3. 3.3 Global Gastrointestinal Company Ranking (2024-2026)
  4. 3.4 Global Gastrointestinal Company Manufacturing Base and Headquarters
  5. 3.5 Global Gastrointestinal Company Product Type and Application
  6. 3.6 Global Gastrointestinal Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gastrointestinal Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gastrointestinal Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gastrointestinal Market by Type
  1. 4.1 Gastrointestinal Type Introduction
  2. 4.1.1 Prescription Gastrointestinal Drug
  3. 4.1.2 OTC Gastrointestinal Drug
  4. 4.2 Global Gastrointestinal Sales Value by Type
  5. 4.2.1 Global Gastrointestinal Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gastrointestinal Sales Value by Type (2021-2032)
  7. 4.2.3 Global Gastrointestinal Sales Value Share by Type (2021-2032)
5 Gastrointestinal Market by Application
  1. 5.1 Gastrointestinal Application Introduction
  2. 5.1.1 Chronic Gastritis
  3. 5.1.2 Functional Dyspepsia
  4. 5.1.3 Peptic Ulcer
  5. 5.1.4 Acute Gastroenteritis
  6. 5.1.5 Others
  7. 5.2 Global Gastrointestinal Sales Value by Application
  8. 5.2.1 Global Gastrointestinal Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Gastrointestinal Sales Value by Application (2021-2032)
  10. 5.2.3 Global Gastrointestinal Sales Value Share by Application (2021-2032)
6 Gastrointestinal Regional Value Analysis
  1. 6.1 Global Gastrointestinal Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastrointestinal Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gastrointestinal Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gastrointestinal Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gastrointestinal Sales Value (2021-2032)
  7. 6.3.2 North America Gastrointestinal Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gastrointestinal Sales Value (2021-2032)
  10. 6.4.2 Europe Gastrointestinal Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gastrointestinal Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gastrointestinal Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gastrointestinal Sales Value (2021-2032)
  16. 6.6.2 South America Gastrointestinal Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gastrointestinal Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gastrointestinal Sales Value Share by Country, 2025 VS 2032
7 Gastrointestinal Country-level Value Analysis
  1. 7.1 Global Gastrointestinal Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gastrointestinal Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gastrointestinal Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gastrointestinal Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gastrointestinal Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gastrointestinal Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gastrointestinal Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gastrointestinal Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gastrointestinal Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gastrointestinal Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gastrointestinal Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gastrointestinal Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gastrointestinal Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gastrointestinal Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gastrointestinal Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gastrointestinal Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gastrointestinal Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gastrointestinal Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gastrointestinal Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gastrointestinal Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gastrointestinal Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gastrointestinal Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gastrointestinal Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gastrointestinal Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gastrointestinal Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gastrointestinal Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gastrointestinal Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gastrointestinal Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gastrointestinal Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gastrointestinal Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gastrointestinal Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gastrointestinal Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gastrointestinal Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gastrointestinal Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gastrointestinal Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZenec
  2. 8.1.1 AstraZenec Company Information
  3. 8.1.2 AstraZenec Business Overview
  4. 8.1.3 AstraZenec Gastrointestinal Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZenec Gastrointestinal Product Portfolio
  6. 8.1.5 AstraZenec Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Gastrointestinal Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Gastrointestinal Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Gastrointestinal Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Gastrointestinal Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Gastrointestinal Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Gastrointestinal Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Gastrointestinal Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Gastrointestinal Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Teva
  32. 8.6.1 Teva Company Information
  33. 8.6.2 Teva Business Overview
  34. 8.6.3 Teva Gastrointestinal Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Teva Gastrointestinal Product Portfolio
  36. 8.6.5 Teva Recent Developments
  37. 8.7 Zeria（Tillotts）
  38. 8.7.1 Zeria（Tillotts） Company Information
  39. 8.7.2 Zeria（Tillotts） Business Overview
  40. 8.7.3 Zeria（Tillotts） Gastrointestinal Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Zeria（Tillotts） Gastrointestinal Product Portfolio
  42. 8.7.5 Zeria（Tillotts） Recent Developments
  43. 8.8 Perrigo
  44. 8.8.1 Perrigo Company Information
  45. 8.8.2 Perrigo Business Overview
  46. 8.8.3 Perrigo Gastrointestinal Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Perrigo Gastrointestinal Product Portfolio
  48. 8.8.5 Perrigo Recent Developments
  49. 8.9 Boehringer Ingelheim
  50. 8.9.1 Boehringer Ingelheim Company Information
  51. 8.9.2 Boehringer Ingelheim Business Overview
  52. 8.9.3 Boehringer Ingelheim Gastrointestinal Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Boehringer Ingelheim Gastrointestinal Product Portfolio
  54. 8.9.5 Boehringer Ingelheim Recent Developments
  55. 8.10 Purdue Pharma
  56. 8.10.1 Purdue Pharma Company Information
  57. 8.10.2 Purdue Pharma Business Overview
  58. 8.10.3 Purdue Pharma Gastrointestinal Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Purdue Pharma Gastrointestinal Product Portfolio
  60. 8.10.5 Purdue Pharma Recent Developments
  61. 8.11 C.B. Fleet
  62. 8.11.1 C.B. Fleet Company Information
  63. 8.11.2 C.B. Fleet Business Overview
  64. 8.11.3 C.B. Fleet Gastrointestinal Revenue and Gross Margin (2021-2026)
  65. 8.11.4 C.B. Fleet Gastrointestinal Product Portfolio
  66. 8.11.5 C.B. Fleet Recent Developments
  67. 8.12 Abbott
  68. 8.12.1 Abbott Company Information
  69. 8.12.2 Abbott Business Overview
  70. 8.12.3 Abbott Gastrointestinal Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Abbott Gastrointestinal Product Portfolio
  72. 8.12.5 Abbott Recent Developments
  73. 8.13 Jiangzhong
  74. 8.13.1 Jiangzhong Company Information
  75. 8.13.2 Jiangzhong Business Overview
  76. 8.13.3 Jiangzhong Gastrointestinal Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Jiangzhong Gastrointestinal Product Portfolio
  78. 8.13.5 Jiangzhong Recent Developments
  79. 8.14 Xian-Janssen
  80. 8.14.1 Xian-Janssen Company Information
  81. 8.14.2 Xian-Janssen Business Overview
  82. 8.14.3 Xian-Janssen Gastrointestinal Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Xian-Janssen Gastrointestinal Product Portfolio
  84. 8.14.5 Xian-Janssen Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst